Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus

被引：12
作者：
Anderson, Ryan Taylor [1 ]
Lim, Seng Gee [2 ]
Mishra, Poonam [3 ]
Josephson, Filip [4 ]
Donaldson, Eric [3 ]
Given, Bruce [5 ]
Miller, Veronica [1 ]
机构：
[1] Univ Calif Berkeley, Washington, DC 20036 USA
[2] Natl Univ Singapore, Singapore, Singapore
[3] US FDA, Silver Spring, MD USA
[4] Swedish Med Prod Agcy, Uppsala, Sweden
[5] Arrowhead Pharmaceut Inc, Pasadena, CA USA
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 03期
关键词：
TENOFOVIR DISOPROXIL FUMARATE; ACUTE EXACERBATION; ANTIVIRAL THERAPY; LAMIVUDINE; FLARES; RISK; CLEARANCE; INFECTION; DRUGS;
D O I：
10.1053/j.gastro.2018.11.062
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：529 / +
页数：9
相关论文
共 47 条
[1]  
[Anonymous], 2010, Notice. Fed. Regist, V75, P3471
[2]   Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study [J].
Berg, Thomas ;
Simon, Karl-Georg ;
Mauss, Stefan ;
Schott, Eckart ;
Heyne, Renate ;
Klass, Dietmar M. ;
Eisenbach, Christoph ;
Welzel, Tania Mara ;
Zachoval, Reinhart ;
Felten, Gisela ;
Schulze-zur-Wiesch, Julian ;
Cornberg, Markus ;
Op den Brouw, Marjoleine L. ;
Jump, Belinda ;
Reiser, Hans ;
Gallo, Lothar ;
Warger, Tobias ;
Petersen, Joerg .
JOURNAL OF HEPATOLOGY, 2017, 67 (05) :918-924
[3]   Impact of non-alcoholic fatty liver disease on chronic hepatitis B [J].
Bondini, Silvia ;
Kallman, Jillian ;
Wheeler, Angela ;
Prakash, Shivaani ;
Gramlich, Terry ;
Jondle, Daniel M. ;
Younossi, Zobair M. .
LIVER INTERNATIONAL, 2007, 27 (05) :607-611
[4]   High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C [J].
Bressler, BL ;
Guindi, M ;
Tomlinson, G ;
Heathcote, J .
HEPATOLOGY, 2003, 38 (03) :639-644
[5]   Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis C in the era of new oral direct-acting antivirals: A concise review [J].
Burgess, Sarah V. ;
Hussaini, Trana ;
Yoshida, Eric M. .
ANNALS OF HEPATOLOGY, 2016, 15 (02) :154-159
[6]   Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management [J].
Chang, Ming-Ling ;
Liaw, Yun-Fan .
JOURNAL OF HEPATOLOGY, 2014, 61 (06) :1407-1417
[7]   A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B [J].
Chang, TT ;
Gish, RG ;
de Man, R ;
Gadano, A ;
Sollano, J ;
Chao, YC ;
Lok, AS ;
Han, KH ;
Goodman, Z ;
Zhu, J ;
Cross, A ;
DeHertogh, D ;
Wilber, R ;
Colonno, R ;
Apelian, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1001-1010
[8]   When can we stop nucleoside analogues in patients with chronic hepatitis B? [J].
Chong, Chern Hao ;
Lim, Seng Gee .
LIVER INTERNATIONAL, 2017, 37 :52-58
[9]   Animal models of HBV infection [J].
Dandri, Maura ;
Petersen, Joerg .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2017, 31 (03) :273-279
[10]   Drugs in Development for Hepatitis B [J].
Dawood, Altaf ;
Basit, Syed Abdul ;
Jayaraj, Mahendran ;
Gish, Robert G. .
DRUGS, 2017, 77 (12) :1263-1280
12345